• Consensus Rating: Buy
  • Consensus Price Target: $121.00
  • Forecasted Upside: 141.81 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$50.04
▼ -0.14 (-0.28%)

This chart shows the closing price for SNY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sanofi Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNY

Analyst Price Target is $121.00
▲ +141.81% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is $121.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 141.81% upside from the last price of $50.04.

This chart shows the closing price for SNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Sanofi.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2022UBS GroupLower Price TargetBuy ➝ Buy$122.00 ➝ $121.00Low
(Data available from 7/7/2017 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 4 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
4/8/2022
  • 4 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
6/7/2022
  • 6 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/7/2022

Current Sentiment

  • 6 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Sanofi logo
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Read More

Today's Range

Now: $50.04
Low: $49.57
High: $50.12

50 Day Range

MA: $52.19
Low: $48.99
High: $56.29

52 Week Range

Now: $50.04
Low: $46.92
High: $58.10

Volume

2,223,662 shs

Average Volume

2,192,212 shs

Market Capitalization

$126.47 billion

P/E Ratio

N/A

Dividend Yield

2.51%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sanofi?

The following Wall Street analysts have issued reports on Sanofi in the last twelve months: StockNews.com, and UBS Group AG.
View the latest analyst ratings for SNY.

What is the current price target for Sanofi?

0 Wall Street analysts have set twelve-month price targets for Sanofi in the last year. Their average twelve-month price target is $121.00, suggesting a possible upside of 141.8%.
View the latest price targets for SNY.

What is the current consensus analyst rating for Sanofi?

Sanofi currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNY will outperform the market and that investors should add to their positions of Sanofi.
View the latest ratings for SNY.

How do I contact Sanofi's investor relations team?

Sanofi's physical mailing address is 54 Rue la Boetie, Paris, Ile De France 75008. The company's listed phone number is (315) 377-4000. The official website for Sanofi is www.sanofi.com. Learn More about contacing Sanofi investor relations.